...
axsm-img

Axsome Therapeutics Inc, Common Stock

AXSM

NMQ

$90.1

-$4.27

(-4.52%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$4.74B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
568.48K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.25
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$64.11 L
$105 H
$90.1

About Axsome Therapeutics Inc, Common Stock

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameAXSMSectorS&P500
1-Week Return-9.99%-2.27%-0.57%
1-Month Return-7.9%-3.96%1.21%
3-Month Return-3.81%-9.7%7.57%
6-Month Return24.26%-3.37%11.45%
1-Year Return21.04%3.71%28.48%
3-Year Return176.8%3.8%29.52%
5-Year Return92.56%39.78%90.66%
10-Year Return930.89%106.91%203.75%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue--8.82M50.04M270.60M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":3.26,"profit":true},{"date":"2022-12-31","value":18.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue37.33K77.72K1.16M5.20M26.07M[{"date":"2019-12-31","value":0.14,"profit":true},{"date":"2020-12-31","value":0.3,"profit":true},{"date":"2021-12-31","value":4.43,"profit":true},{"date":"2022-12-31","value":19.94,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(37.33K)(77.72K)(1.16M)44.84M244.53M[{"date":"2019-12-31","value":-0.02,"profit":false},{"date":"2020-12-31","value":-0.03,"profit":false},{"date":"2021-12-31","value":-0.47,"profit":false},{"date":"2022-12-31","value":18.34,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin--(13.10%)89.61%90.37%[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-14.5,"profit":false},{"date":"2022-12-31","value":99.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses67.11M99.09M124.71M221.34M476.36M[{"date":"2019-12-31","value":14.09,"profit":true},{"date":"2020-12-31","value":20.8,"profit":true},{"date":"2021-12-31","value":26.18,"profit":true},{"date":"2022-12-31","value":46.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(67.25M)(99.14M)(124.71M)(176.50M)(231.82M)[{"date":"2019-12-31","value":-6724509700,"profit":false},{"date":"2020-12-31","value":-9914132800,"profit":false},{"date":"2021-12-31","value":-12470693000,"profit":false},{"date":"2022-12-31","value":-17650082500,"profit":false},{"date":"2023-12-31","value":-23182500000,"profit":false}]
Total Non-Operating Income/Expense(2.34M)(6.38M)(11.39M)(14.67M)(12.91M)[{"date":"2019-12-31","value":-233962600,"profit":false},{"date":"2020-12-31","value":-637868800,"profit":false},{"date":"2021-12-31","value":-1139212400,"profit":false},{"date":"2022-12-31","value":-1466924700,"profit":false},{"date":"2023-12-31","value":-1290600000,"profit":false}]
Pre-Tax Income(68.35M)(102.90M)(130.40M)(187.13M)(238.28M)[{"date":"2019-12-31","value":-6834518600,"profit":false},{"date":"2020-12-31","value":-10290060000,"profit":false},{"date":"2021-12-31","value":-13040299200,"profit":false},{"date":"2022-12-31","value":-18713365100,"profit":false},{"date":"2023-12-31","value":-23827800000,"profit":false}]
Income Taxes1.34M2.49M4.54M10.63M960.00K[{"date":"2019-12-31","value":12.62,"profit":true},{"date":"2020-12-31","value":23.4,"profit":true},{"date":"2021-12-31","value":42.7,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":9.03,"profit":true}]
Income After Taxes(69.69M)(105.39M)(134.94M)(197.77M)(239.24M)[{"date":"2019-12-31","value":-6968684100,"profit":false},{"date":"2020-12-31","value":-10538872000,"profit":false},{"date":"2021-12-31","value":-13494339100,"profit":false},{"date":"2022-12-31","value":-19776647700,"profit":false},{"date":"2023-12-31","value":-23923800000,"profit":false}]
Income From Continuous Operations(68.35M)(102.95M)(130.40M)(187.13M)(239.24M)[{"date":"2019-12-31","value":-6834518600,"profit":false},{"date":"2020-12-31","value":-10295417800,"profit":false},{"date":"2021-12-31","value":-13040299200,"profit":false},{"date":"2022-12-31","value":-18713365100,"profit":false},{"date":"2023-12-31","value":-23923800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(69.69M)(105.39M)(134.94M)(197.77M)(239.24M)[{"date":"2019-12-31","value":-6968684100,"profit":false},{"date":"2020-12-31","value":-10538872000,"profit":false},{"date":"2021-12-31","value":-13494339100,"profit":false},{"date":"2022-12-31","value":-19776647700,"profit":false},{"date":"2023-12-31","value":-23923800000,"profit":false}]
EPS (Diluted)(2.00)(2.73)(3.47)(4.57)(5.20)[{"date":"2019-12-31","value":-200,"profit":false},{"date":"2020-12-31","value":-273,"profit":false},{"date":"2021-12-31","value":-347,"profit":false},{"date":"2022-12-31","value":-457,"profit":false},{"date":"2023-12-31","value":-520,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

AXSM
Cash Ratio 1.67
Current Ratio 2.44
Quick Ratio 2.37

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

AXSM
ROA (LTM) -26.44%
ROE (LTM) -171.61%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

AXSM
Debt Ratio Lower is generally better. Negative is bad. 0.83
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.17

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

AXSM
Trailing PE NM
Forward PE NM
P/S (TTM) 13.99
P/B 49.23
Price/FCF NM
EV/R 13.11
EV/Ebitda NM
PEG NM

FAQs

What is Axsome Therapeutics Inc share price today?

Axsome Therapeutics Inc (AXSM) share price today is $90.1

Can Indians buy Axsome Therapeutics Inc shares?

Yes, Indians can buy shares of Axsome Therapeutics Inc (AXSM) on Vested. To buy Axsome Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AXSM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Axsome Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Axsome Therapeutics Inc (AXSM) via the Vested app. You can start investing in Axsome Therapeutics Inc (AXSM) with a minimum investment of $1.

How to invest in Axsome Therapeutics Inc shares from India?

You can invest in shares of Axsome Therapeutics Inc (AXSM) via Vested in three simple steps:

  • Click on Sign Up or Invest in AXSM stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Axsome Therapeutics Inc shares
What is Axsome Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Axsome Therapeutics Inc (AXSM) is $105. The 52-week low price of Axsome Therapeutics Inc (AXSM) is $64.11.

What is Axsome Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Axsome Therapeutics Inc (AXSM) is

What is Axsome Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Axsome Therapeutics Inc (AXSM) is 49.23

What is Axsome Therapeutics Inc dividend yield?

The dividend yield of Axsome Therapeutics Inc (AXSM) is 0.00%

What is the Market Cap of Axsome Therapeutics Inc?

The market capitalization of Axsome Therapeutics Inc (AXSM) is $4.74B

What is Axsome Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Axsome Therapeutics Inc is AXSM

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top